

# AD-HOC ANNOUNCEMENT

(pursuant to section 15 WpHG)

MeVis Medical Solutions AG  
Caroline-Herschel-Str. 1  
28359 Bremen  
Germany

Phone: +49 421 224 95 0  
Fax: +49 421 22495 999  
E-mail: [ir@mevis.de](mailto:ir@mevis.de)

## **MeVis Medical Solutions AG: Executive Board and Supervisory Board welcome public takeover offer of VMS Deutschland Holdings GmbH**

**Bremen, December 17, 2014** – Today, VMS Deutschland Holdings GmbH based in Darmstadt, an affiliate of Varian Medical Systems, Inc., Palo Alto, California, USA, has published pursuant to Section 10 WpÜG its decision to make a voluntary public takeover offer to all shareholders of MeVis Medical Solutions AG to acquire their registered non-par value shares against payment of EUR 17.50 per share. The offer is intended to be subject to the condition of a minimum acceptance rate of 75 % of the shares issued by MeVis Medical Solutions AG (excluding treasury shares).

According to the VMS Deutschland Holdings GmbH a number of major shareholders have irrevocably undertaken to accept the offer of the VMS Deutschland Holdings GmbH; this corresponds to a total of over 70 % of the shares issued by the MeVis Medical Solutions AG (excluding treasury shares).

The Executive Board and Supervisory Board of the MeVis Medical Solutions AG will carefully review the offer and publish a statement pursuant to § 27 WpÜG within two weeks after publication of the offer document. According to their initial assessment the Executive Board and Supervisory Board welcome the offer in principal and consider Varian Medical Systems a reliable partner for the further development of the MeVis Medical Solutions AG.

Varian Medical Systems is the world's leading manufacturer of medical devices and software for treating cancer and other diseases through radiotherapy, proton therapy, and brachytherapy.

\*\*\*\*\*

*MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.*

*Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.*